The government needs to quash fears about safety of the rubella vaccine and establish its efficacy to achieve its goal of eliminating the disease by 2020
The Union Health Ministry is leaving no stone unturned to eliminate and control congenital rubella syndrome (CRS) by 2020, a disease that causes birth defects such as irreversible deafness and blindness in nearly 40,000 children every year. In a bid to eradicate the rubella virus and achieve success as in the case of polio and maternal and neonatal tetanus, the health ministry has launched a concerted, nation-wide measles-rubella vaccination (MR-VAC) campaign for children aged between nine months and 15 years.
However, phase-1 of the campaign which covers Karnataka, Tamil Nadu, Goa, Puducherry and Lakshadweep has encountered a roadblock in the form of a controversy. There is a rumour going around through Whatsapp messages, SMS alerts, text and AV clips on social media forums that the vaccine is banned in the US as it causes serious side effects which include damaging a child’s immunity and memory. It is being pushed in India by the global pharma industry which is looking for a market to dump substandard products.
However, the Ministry remains undeterred in its course. Claiming that the government faces these hurdles each time a new vaccination campaign is launched, Dr Pradeep Haldar, Deputy Commissioner (Immunisation), Union Ministry of Health says, “During the polio vaccine campaign, we faced a similar kind of situation where people had a mistrust on the immunisation programme. Whenever the government has a targeted eradication campaign and tries to reach the last mile on a targeted time frame such an issue arises. But the government is well prepared to overcome these challenges. However, now they are bigger as the size of the number of children to be covered is three times more than what we did for polio programme. We are covering from children aged from nine months to 15 years.”
Diese Geschichte stammt aus der April 01 2017-Ausgabe von Express Pharma.
Starten Sie Ihre 7-tägige kostenlose Testversion von Magzter GOLD, um auf Tausende kuratierte Premium-Storys sowie über 8.000 Zeitschriften und Zeitungen zuzugreifen.
Bereits Abonnent ? Anmelden
Diese Geschichte stammt aus der April 01 2017-Ausgabe von Express Pharma.
Starten Sie Ihre 7-tägige kostenlose Testversion von Magzter GOLD, um auf Tausende kuratierte Premium-Storys sowie über 8.000 Zeitschriften und Zeitungen zuzugreifen.
Bereits Abonnent? Anmelden
Nutraceutical M&As: How strategic mergers are shaping the health and wellness market
The nutraceutical industry has seen a surge in M&A activity over the past three years as companies pursue strategic acquisitions to strengthen market positions, diversify offerings, and drive innovation. Sudhindran N, GM - Corporate Affairs, Nutrify Today explores key trends, motivations, notable deals, and future growth prospects shaping the industry
Rising research costs, complex drug systems, stringent regulations, and global pressures pose major threats to pharma R&D
According to one of the published reports, the pharma industry invested about $83 billion in R&D in 2019, which is about 10 times the research and development (R&D) spent per year in the 1980s, after adjusting for the effects of inflation.
Harnessing data analytics to propel drug discovery and development in 2025
As the pharma landscape evolves, data analytics will be at the forefront of drug discovery and development, transforming traditional methods. By leveraging data-driven insights, companies can expedite R&D, optimise clinical trials, and personalise treatments, bringing life-saving therapies to market more efficiently, explains Biju Davis, SVP, Engineering, Model N
Strengthening our presence within APAC through increased penetration is a key focus
Aanchal Tomar, Executive Director, Asia Pacific, Lonza Capsules Health Ingredients speaks about Lonza Capsules Health Ingredients’ strategic growth, challenges, and sustainability initiatives in the APAC market, showcasing their innovative capsule solutions and health ingredients that cater to the region's diverse pharmaceutical and nutraceutical needs, in an interview with Express Pharma
Responsible Sourcing and Manufacturing: Growing towards a sustainable future with Lonza
In response to the establishment of environmental impact targets by the pharmaceutical industry, Lonza promotes responsible sourcing practices, sustainable manufacturing standards, and renewable energy utilisation showcasing that responsible manufacturing can assist our customers to reach their sustainability goals, highlights Christine Lebeault, Head of Applied Sustainability, Lonza Capsules and Health Ingredients
Rethinking R&D to balance efficiency, innovation and sustainability
In an era of skyrocketing research costs and complex drug delivery challenges, pharma industry leaders share their insights on adopting advanced technologies, data-driven decision-making, and sustainable practices to optimise R&D and drive impactful therapies to market
Powerful Process Control with IND500x Weighing Indicators
Ensuring consistent quality in hazardous environments, particularly in Ex-Areas (Zone 1/21, Division 1), is a critical aspect of industrial operations. The IND500x weighing indicators from METTLER TOLEDO provide a robust solution for these challenging settings, offering optimized safety and productivity.
Ensuring clean room integrity with prime clean reset high-speed doors
Prime Clean Reset high-speed doors ensure airtight seals, minimising air permeability and contamination in clean rooms. Designed for sensitive environments, they enhance operational efficiency and meet rigorous regulatory standards, making them ideal for pharmaceutical and biotech industries
Complete environmental monitoring solution - testo Saveris Pharma
There are several critical applications in the industry like research and development that demand for continuous & reliable monitoring of important environmental parameters.
Adaptive Manufacturing:-The new flexibility in medical device assembly
Unlike traditional, rigid production lines, B&R's adaptive machines seamlessly adjust to the requirements of each device, dynamically adapting to each unique process